摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

rac-methyl 2,4-dimethyl-6-oxocyclohex-1-enecarboxylate | 1204592-93-7

中文名称
——
中文别名
——
英文名称
rac-methyl 2,4-dimethyl-6-oxocyclohex-1-enecarboxylate
英文别名
Methyl 2,4-dimethyl-6-oxocyclohex-1-enecarboxylate;methyl 2,4-dimethyl-6-oxocyclohexene-1-carboxylate
rac-methyl 2,4-dimethyl-6-oxocyclohex-1-enecarboxylate化学式
CAS
1204592-93-7
化学式
C10H14O3
mdl
——
分子量
182.219
InChiKey
OUGHBHRBIMMGAX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.3
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    43.4
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    rac-methyl 2,4-dimethyl-6-oxocyclohex-1-enecarboxylate3-溴联苯正丁基锂copper(l) cyanide 作用下, 以 hexanes 、 乙醚 为溶剂, 反应 3.67h, 生成 methyl (2RS,4RS)-2-(3-phenylphenyl)-2,4-dimethyl-6-oxocyclohexanecarboxylate
    参考文献:
    名称:
    [EN] CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
    [FR] CYCLOHEXÉNYLES COMME MODULATEURS DE L'ACTIVITÉ DES RÉCEPTEURS DE CHIMIOKINES
    摘要:
    公开号:
    WO2010009068A3
  • 作为产物:
    参考文献:
    名称:
    Discovery and synthesis of cyclohexenyl derivatives as modulators of CC chemokine receptor 2 activity
    摘要:
    A novel cyclohexenyl series of CCR2 antagonists has been discovered. This series of small, rigid compounds exhibits submicromolar binding affinity for CCR2. Modification of the substituents on the cyclohexene ring led to the identification of potent CCR2 antagonists. Progress from initial lead 5 (IC50 = 700 nM) to (-)-38 (IC50 = 9.0 nM) is discussed. (C) 2015 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2015.11.051
点击查看最新优质反应信息

文献信息

  • CYCLOHEXENYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
    申请人:Carter Percy H.
    公开号:US20110118354A1
    公开(公告)日:2011-05-19
    The present application describes modulators of MCP-1 or CCR-2 of formula, (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein T, W, X, Y, Z, R 1 , R 2 , R 4 and R 6 , are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula, (I) are disclosed.
    本申请描述了 MCP-1 或 CCR-2 的调节剂的公式,(I) 或其立体异构体或前药或药学上可接受的盐,其中 T、W、X、Y、Z、R1、R2、R4 和 R6 在此定义。此外,还公开了使用公式 (I) 的调节剂治疗和预防炎症性疾病,如哮喘和过敏疾病,以及自身免疫病理学,如类风湿性关节炎和移植排斥等方法。
  • Cyclohexenyl modulators of chemokine receptor activity
    申请人:Carter Percy H.
    公开号:US08507559B2
    公开(公告)日:2013-08-13
    The present application describes modulators of MCP-1 or CCR-2 of formula, (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein T, W, X, Y, Z, R1, R2, R4 and R6, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula, (I) are disclosed.
    本申请描述了MCP-1或CCR-2的调节剂的公式(I)或其立体异构体或前药或药物可接受的盐,其中T、W、X、Y、Z、R1、R2、R4和R6在此定义。此外,本文揭示了使用公式(I)的调节剂治疗和预防炎症性疾病,如哮喘和过敏性疾病,以及自身免疫病理,如类风湿性关节炎和移植排斥等方法。
  • CYCLOHEXENYL COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
    申请人:Bristol-Myers Squibb Company
    公开号:EP2318352B1
    公开(公告)日:2012-12-19
  • US8507559B2
    申请人:——
    公开号:US8507559B2
    公开(公告)日:2013-08-13
  • Discovery and synthesis of cyclohexenyl derivatives as modulators of CC chemokine receptor 2 activity
    作者:Gregory D. Brown、Qing Shi、George V. Delucca、Douglas G. Batt、Michael A. Galella、Mary-Ellen Cvijic、Rui-Qin Liu、Feng Qiu、Qihong Zhao、Joel C. Barrish、Percy H. Carter
    DOI:10.1016/j.bmcl.2015.11.051
    日期:2016.1
    A novel cyclohexenyl series of CCR2 antagonists has been discovered. This series of small, rigid compounds exhibits submicromolar binding affinity for CCR2. Modification of the substituents on the cyclohexene ring led to the identification of potent CCR2 antagonists. Progress from initial lead 5 (IC50 = 700 nM) to (-)-38 (IC50 = 9.0 nM) is discussed. (C) 2015 Elsevier Ltd. All rights reserved.
查看更多